Crizotinib (Xalkori) — targeted treatment for ALK- or ROS1-positive lung cancer

What crizotinib is in simple patient language

Xalkori — brand name. Crizotinib — the drug name in medical records. A cancer capsule. A targeted drug. Not routine chemotherapy. Not immunotherapy. Not a tablet to run without an oncologist.

Why it comes up: start with the report, not with the brand name. If ALK or ROS1 is not clearly written there, Xalkori is probably not the right discussion. If it is there, the drug can enter the list.

I look at the actual testing page: date, lab, sample, and exact wording. Then I put it next to the scans, brain MRI if relevant, liver numbers, pulse, eye complaints, breathing, and everyday medicines. One missing page can change the answer.

How crizotinib works

Some tumors run on a signal that is stuck on. ALK or ROS1 can behave like that. The cell keeps hearing go, go, go, even when the body did not ask for more growth.

Crizotinib tries to quiet that message. If the tumor really depends on it, the cancer may slow down. Spots may shrink. Sometimes the first useful sign is less movement on scans, not a dramatic change in how the patient feels.

The capsule is taken at home. The decision is still medical. The doctor reads the molecular report together with scans, symptoms, liver tests, pulse, ECG when needed, vision changes, and lung complaints.

Which diseases crizotinib may be used for

Crizotinib is not a general lung cancer drug. It is discussed only when the biology points in that direction.

• lung cancer with an ALK rearrangement, when a targeted ALK plan is being considered
• lung cancer with a ROS1 rearrangement, if the clinical setting fits
• spread-out disease that needs treatment for the whole body
• a plan review when Xalkori was offered and the reason is not fully clear
• comparison with other targeted drugs in the same disease area
• rare ALK-linked tumors only in a specialist discussion, not by guess

Same word on the biopsy is not enough. Two patients can both have lung cancer, but the test result, brain findings, earlier drugs, breathing, liver function, and strength may lead to different choices.

When crizotinib can be especially relevant

It usually enters the discussion after the tumor report gives the doctor a real molecular reason to look at ALK or ROS1 treatment.

• ALK or ROS1 is confirmed in a useful report
• local treatment alone is not enough
• the team needs a systemic targeted step
• the patient already received another plan and the next move is being checked
• there are questions about brain control, lung symptoms, vision, liver values, or heart rhythm
• the family wants a second opinion before starting or changing treatment

The question is not whether the drug is famous. The question is what job it has now: shrink disease, slow it, hold control, or serve as a safer bridge while the next step is planned.

What needs to be checked before treatment

One short discharge note is rarely enough. The doctor needs the tumor story and the patient story.

• pathology report and exact lung cancer type
• ALK, ROS1, and other molecular results, with the testing method if shown
• where the sample came from and when it was taken
• fresh CT or PET-CT used to judge the disease
• brain MRI if there were neurologic symptoms or if the oncologist needs it for staging
• what treatment was already given, when it helped, and why it stopped
• CBC and chemistry panel
• liver and kidney values
• pulse history, ECG notes, fainting, dizziness, or rhythm problems
• vision complaints: flashes, blur, eye pain, strange light effects
• breathing changes, cough pattern, chest discomfort, swelling, or marked weakness
• full medication list, including heart drugs, pressure pills, antifungals, antibiotics, sleep tablets, herbs, and supplements

Sometimes the start waits. Not because the molecular result is useless. Because the lungs need another check, the liver numbers are not calm, the pulse is too slow, or another medicine makes the plan unsafe.

How treatment with crizotinib goes

Crizotinib is taken by mouth on the schedule given by the oncologist. No changing capsule numbers at home. No stopping for a few days and restarting by guess.

Home treatment can look simple from outside. It is not simple inside the body. Early weeks are watched for tolerance. Later, scans and labs show whether the same plan still makes sense.

What usually gets watched:

• how the patient feels day to day
• liver values
• pulse, ECG if needed, dizziness, fainting, or heart fluttering
• eyesight changes or new eye pain
• breathing, cough, chest heaviness, or new lung symptoms
• swelling around the eyes, legs, or feet
• nausea, stool, appetite, weight, tiredness
• planned scans for disease trend

A side effect does not always end the drug. A pause, dose change, symptom treatment, ECG check, or extra blood work may be enough. The doctor decides the safe move.

Possible side effects

The pattern is not the same for every patient. One person mainly has nausea. Another has swelling. Another gets visual symptoms, slow pulse, or liver-test changes.

What can happen:

• nausea, vomiting, loose stool, constipation, or stomach discomfort
• tiredness, low appetite, weight change
• swelling near the eyes, ankles, feet, or legs
• light flashes, blurry vision, or other eye changes
• liver blood tests moving in the wrong direction
• slow pulse, dizziness, fainting, or heart-rhythm symptoms
• new cough, harder breathing, or lung inflammation concern
• blood-count or chemistry changes

Do not wait until a symptom becomes dramatic. A small change reported early is often easier to handle than a late complication.

When the treating team needs to know fast

Do not save these symptoms for the next routine visit:

• breathing becomes harder or changes quickly
• cough comes with fever, chest pressure, or fast decline
• skin color looks yellow, urine becomes very dark, or right-side upper belly pain appears
• pulse becomes unusually slow, the heart feels irregular, or dizziness is strong
• fainting, near-fainting, or sudden heavy weakness
• eyesight changes fast, the eye hurts, or vision becomes sharply worse
• swelling grows quickly, especially with breath trouble
• vomiting keeps coming back, stool is severe, or drinking is not working
• the patient suddenly looks much worse without a clear reason

Do not sit at home trying to prove whether Xalkori caused it. The treating team should make that call.

Why crizotinib is not right for everyone

Crizotinib can be useful in the right case. It is still not a universal lung cancer capsule.

The doctor may choose another path if:

• ALK or ROS1 is not confirmed, or the result is not enough for a decision
• another target is more important in this tumor
• brain disease, if present, needs a different strategy
• liver values are already unsafe for this plan
• pulse is too slow, rhythm problems are active, or medicines clash with the drug
• new lung symptoms need explanation first
• the patient is too weak for this kind of treatment
• the disease needs a faster or different move

Choosing something else does not mean Xalkori is a bad drug. It may simply be the wrong tool for this moment.

Can crizotinib be combined with other treatments

Sometimes, yes. But more treatment is not automatically better treatment. Each part needs a reason.

• radiation to selected spots when that belongs to the full plan
• local treatment or a procedure if one area needs separate control
• support for nausea, stool problems, swelling, or skin symptoms
• review of medicines that affect rhythm, liver handling, or drug levels
• a switch to another targeted drug if the disease starts moving again
• clinical trial discussion when standard choices are limited

Sequence matters. The doctor has to know what comes first, what is being watched, and what would make the plan change.

What no quick response can mean

A fast visible effect is not guaranteed. The patient may already be taking capsules, while the first scans are still ahead.

Good news is not always dramatic. Sometimes spots shrink. Sometimes the disease stops running as fast. Symptoms do not build. Breathing is not worse. Labs allow treatment to continue.

One feeling in one week is not enough. Scans, cough, breathing, weight, liver tests, heart symptoms, side effects, and the earlier speed of the disease need to be read together.

Oncology consultation in Israel about crizotinib

At Tel Aviv Medical Clinic, a patient with ALK- or ROS1-positive lung cancer can discuss whether crizotinib has a place in the current plan. This is useful when Xalkori was offered, but the goal, risks, or alternatives are not clear.

A consultation may help to:

• read the ALK or ROS1 report in context
• understand why this drug is being discussed now
• compare Xalkori with other targeted options
• review liver, heart-rhythm, vision, lung, and medicine risks
• prepare questions for the treating oncologist
• discuss which options may be relevant in Israel

We do not prescribe remotely and do not replace the treating physician. We help the patient and family understand the medical logic and prepare the documents for the next step.

Frequently asked questions – answered by Dr. Stefanska

1. Is crizotinib the same as chemotherapy?

No. Different idea. Chemo is not the main story here. Xalkori is used only when the tumor file shows a target such as ALK or ROS1.

But home capsules are still cancer treatment. I want liver numbers, pulse, breathing, eye symptoms, swelling, nausea, and the medicine list followed from the start. Not casually. Not by memory.

2. Why do we need the ALK or ROS1 report?

Because the report is the reason for the drug. Without it, Xalkori is just a name, not a treatment plan.

I look at the full page, not one copied line. What was tested. Tissue or blood. Date. Method. Exact result. If the disease has changed after treatment, an old test may need a second look.

3. If ALK or ROS1 is found, is Xalkori always the right tablet?

No. The marker opens the door. It does not finish the decision.

Brain spots, breathing, liver tests, pulse, earlier drugs, side effects, and how fast the cancer is moving can all change the choice. Sometimes Xalkori fits. Sometimes another targeted drug makes more sense.

4. What should I do if my vision changes?

Write it down and tell the team. Light flashes. Blurred picture. New glare. Eye pain. Odd vision at night. I would rather hear about it early than find out a week later.

Call the same day if sight drops suddenly, the eye hurts, the problem spreads, or walking or driving feels unsafe. That is not a symptom to leave for the weekend.

5. What if the pulse is slow or dizziness starts?

Call or send a message. A low number on the pulse screen is only one detail. Low pulse with near-fainting, chest tightness, hard breathing, heavy weakness, or heart medicines needs a real check.

The clinic may want an ECG, blood work, electrolytes, or a look at the medicine list. Do not pause and restart Xalkori by yourself. It makes the story harder to read.

6. How will we know whether Xalkori is working?

Not from one good day. Not from one bad day. The doctor compares scans, cough, breathing, pain, weight, liver tests, pulse, and side effects.

A good answer may be smaller spots. It may also be slower movement after a fast period. If the cancer grows or the drug is too hard to live on, the plan has to be opened again.

7. What should I send before a consultation about Xalkori?

Send the biopsy report, the ALK and ROS1 pages, recent CT or PET-CT, brain MRI if done, blood tests, liver and kidney values, ECG if available, and the full medicine list.

Add a short timeline. Date of diagnosis. What was found. What treatment was tried. What helped. What failed. What side effects were real trouble. That is often more useful than a thick folder with no order.

Important information

This page gives general medical information only. It is not a treatment recommendation. Crizotinib is discussed only after review of the diagnosis, molecular report, scans, prior treatment, blood tests, liver values, heart-rhythm risks, lung symptoms, other illnesses, and the patient’s general condition.

Do not start, stop, or change treatment without speaking with the treating physician.

Contacts

For a consultation about crizotinib:
📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108